Tailored Immunotherapy Approach With Nivolumab ± Nivolumab Plus Ipilimumab as an Immunotherapeutic Boost in Patients With Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
Lancet Oncol 2023 Nov 01;24(11)1252-1265, MO Grimm, E Esteban, P Barthélémy, M Schmidinger, J Busch, BP Valderrama, N Charnley, M Schmitz, U Schumacher, K Leucht, S Foller, G Baretton, I Duran, G de Velasco, F Priou, P Maroto, L AlbigesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.